https://doi.org/10.55788/6f68b5de
Prof. Domenico Bonamonte (Bari University, Italy) discussed the various indications for topical antibiotics, which are widely used in clinical practice [1]. Besides for impetigo, topical antibiotics are also key components in the management of mild-to-moderate skin infections (see Figure). According to Prof. Bonamonte, an ideal topical antibiotic should penetrate the skin efficiently, reach adequate therapeutic doses, minimise cross-resistance, and have a weak sensitisation potential.
Figure: Conditions besides impetigo that may also require topical antibiotics [1]
Fusidic acid became a first-choice treatment option in primary and secondary skin infection due to its efficacy, safety, sensitisation potential, resistance profile, and spectrum selectivity. After topical application, it reaches high antimicrobial concentrations in deep skin layers. Fusidic acid has a high bactericidal activity against S. epidermidis, Streptococcus pyogenes, Propionibacterium acnes, Corynebacterium, Clostridia, and S. aureus, including methicillin-resistant strains [2]. Fusidic acid can not only be used to treat superinfected atopic dermatitis but also for the management of non-infected atopic skin. Since S. aureus releases antigens that sustain the inflammatory reactions in atopic patients, fusidic acid may be applied in combination with corticosteroids in the management of patients with atopic dermatitis. However, studies have not demonstrated any benefits from antibiotic treatment in reducing atopic dermatitis flare-ups.
- Bonamonte D. Indications for topical antibiotics. D1T04.3C, EADV 2020 Virtual Congress, 29-31 Oct.
- Bonamonte D, et al. G Ital Dermatol Venereol 2014;149:453-9.
Posted on
Previous Article
« Chronic inducible urticaria can require some detective work Next Article
Baricitinib in AD: Efficacy paired with consistent long-term results »
« Chronic inducible urticaria can require some detective work Next Article
Baricitinib in AD: Efficacy paired with consistent long-term results »
Table of Contents: EADV 2020
Featured articles
Late-Breaking News
Selective IL-23 blocker shows potential in psoriasis treatment
Promising results with nanobody treatment in psoriasis
Light at the end of the tunnel for chronic hand eczema
Epidermolysis bullosa: Novel wound treatment on the horizon
Efficacious non-steroidal topical for psoriasis
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
COVID-19: What Dermatologists Need to Know
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Much to be learned about COVID-19 and the skin
JAK Inhibitors – A Fascinating Novel Drug Class
JAK inhibitors in AA: re-establishing the immune privilege of hair follicles
JAK1 inhibition successful in hidradenitis suppurativa
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD
Urticaria – What’s new
Chronic inducible urticaria can require some detective work
Chronic spontaneous urticaria: hives, wheals & biomarkers
Ligelizumab for chronic spontaneous urticaria: a new star on the horizon
Infectious Diseases: Novel Developments
Bacterial resistance in skin infections – a challenging threat
Borreliosis: A multifaceted disease
Scabies – A global health challenge
Upcoming Treatments
Meaningful sleep improvement with IL-13 inhibition
Preventing foot odour with zinc oxide coated socks
Baricitinib in AD: Efficacy paired with consistent long-term results
Best of the Posters
Real-world data on brodalumab affirms efficacy and fast onset of action
Heightened risk for psychiatric comorbidities in hidradenitis suppurativa patients
Effects IL-13 blocker improves with longer treatment duration
Related Articles
December 17, 2020
Real-world data on brodalumab affirms efficacy and fast onset of action
December 17, 2020
Scabies – A global health challenge
December 18, 2020
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com